<tei>
    <teiHeader>
        <fileDesc xml:id="_Blome 2020.pdf"/>
    </teiHeader>
    <text xml:lang="en">


		<figure type="table">

            <head>Table </head>
 
            <label>1 </label>
 
            <figDesc>Patient characteristics at first visit (n = 291)<lb/> </figDesc>
<lb/> 
            <table>Characteristics<lb/> n (% of 291)<lb/> Gender<lb/> Male<lb/> 121 (41.6)<lb/> Female<lb/> 170 (58.4)<lb/> Symptoms<lb/> Allergic rhinitis<lb/> 287 (98.6)<lb/> Intermittent a<lb/> 94 (32.5)<lb/> Persistent a<lb/> 195 (67.5)<lb/> Allergic conjunctivitis<lb/> 216 (74.2)<lb/> Severity of rhinoconjunctivitis symptoms b<lb/> Mild<lb/> 59 (20.3)<lb/> Severe<lb/> 232 (79.7)<lb/> Asthma<lb/> 66 (22.7)<lb/> Tree pollen allergy to<lb/> Birch<lb/> 290 (99.7)<lb/> Alder<lb/> 222 (76.3)<lb/> Hazel<lb/> 212 (72.9)<lb/> Concomitant allergies (other than tree pollen)<lb/> No (= monoallergic patient)<lb/> 127 (43.6)<lb/> Yes (= polyallergic patient)<lb/> 164 (56.4)<lb/> Age<lb/> Mean (SD) [years]<lb/> 38.8 (13.0)<lb/> Range [years]<lb/> 18-78<lb/> </table>
<lb/> 
            <note>a According to ARIA classification [17]: Intermittent AR<lb/> symptoms occurring \ 4 days a week OR \ 4 consecutive<lb/> weeks; Persistent AR symptoms occurring [ 4 </note>
 
            <table>days a week<lb/> AND [ 4 consecutive weeks<lb/> b Severe rhinoconjunctivitis was assumed if the sum of the<lb/> severity assessments for rhinitis and conjunctivitis symp-<lb/>toms was C 4, with the following response options for<lb/> each of the two variables (physician global ratings):<lb/> 0 = none, 1 = mild, 2 = moderate, 3 = severe</table>
		</figure>


		<figure type="table">

            <head>Table</head>

            <label>2 </label>
 
            <figDesc>Patient-rated importance of goals in birch pollen sublingual immunotherapy (SLIT) treatment, as measured with<lb/> the Patient Needs Questionnaire (PNQ) within the PBI-AR (first visit; n = 245 patients who completed the PNQ at least<lb/> partially)<lb/> </figDesc>
<lb/> 
            <table>Item (treatment goal)<lb/> As a result of therapy, how<lb/> important is it for you to…<lb/> n<lb/> Importance<lb/> rating<lb/> mean (SD) a<lb/> Does apply:<lb/> n (% of n = 245)<lb/> Importance rating: n (% of n = 245)<lb/> Not at all/somewhat/<lb/> moderately/<lb/> does not apply<lb/> Quite/<lb/> very<lb/> 1. … Not have sneezing impulses<lb/> anymore (S3)<lb/> 245 3.26 (0.99) 243 (99.2)<lb/> 51 (20.8)<lb/> 194 (79.2)<lb/> 2. … No longer have a runny or<lb/> stuffed up nose (S3)<lb/> 245 3.51 (0.83) 244 (99.6)<lb/> 32 (13.1)<lb/> 213 (86.9)<lb/> 3. … Be able to breathe through your<lb/> nose more freely (S3)<lb/> 244 3.45 (0.92) 241 (98.4)<lb/> 32 (13.1)<lb/> 213 (86.9)<lb/> 4. … Feel less fatigued or groggy (S4) 245 2.93 (1.25) 227 (92.7)<lb/> 74 (30.2)<lb/> 171 (69.8)<lb/> 5…. Be able to stay outdoors without<lb/> symptoms (S3)<lb/> 244 3.44 (0.88) 241 (98.4)<lb/> 31 (12.7)<lb/> 214 (87.3)<lb/> 6…. Feel less irritated (S1)<lb/> 245 2.32 (1.49) 213 (86.9)<lb/> 121 (49.4)<lb/> 124 (50.6)<lb/> 7…. Have an easily applicable<lb/> treatment (S2)<lb/> 244 2.87 (1.30) 224 (91.4)<lb/> 81 (33.2)<lb/> 164 (66.8)<lb/> 8…. Not have itching on the eyes,<lb/> nose or palate anymore (S3)<lb/> 245 3.17 (1.26) 232 (94.7)<lb/> 53 (21.6)<lb/> 192 (78.4)<lb/> 9…. Not have burning or watery eyes<lb/> anymore (S3)<lb/> 245 3.17 (1.24) 232 (94.7)<lb/> 54 (22.0)<lb/> 191 (78.0)<lb/> 10…. Be healed of all symptoms (S3) 245 3.16 (1.25) 227 (92.7)<lb/> 50 (20.4)<lb/> 195 (79.6)<lb/> 11…. Be able to sleep better (S1)<lb/> 245 2.75 (1.45) 213 (86.9)<lb/> 83 (34.0)<lb/> 162 (66.0)<lb/> 12…. Feel less depressed (S1)<lb/> 245 2.31 (1.50) 206 (84.1)<lb/> 122 (49.8)<lb/> 123 (50.2)<lb/> 13…. Experience a greater enjoyment<lb/> of life (S1)<lb/> 245 2.32 (1.54) 201 (82.0)<lb/> 120 (49.0)<lb/> 125 (51.0)<lb/> 14…. Have no fear that the disease<lb/> will become worse (S1)<lb/> 245 2.54 (1.49) 212 (86.5)<lb/> 103 (42.0)<lb/> 142 (58.0)<lb/> 15…. Be more productive in everyday<lb/> life (S4)<lb/> 245 2.99 (1.21) 232 (94.7)<lb/> 68 (27.8)<lb/> 177 (72.2)<lb/> 16…. Be able to engage in normal<lb/> leisure activities (S4)<lb/> 244 3.20 (1.05) 238 (97.1)<lb/> 48 (19.7)<lb/> 197 (80.3)<lb/> 17…. Be comfortable showing<lb/> yourself more in public (S1)<lb/> 242 1.93 (1.54) 192 (78.5)<lb/> 147 (59.9)<lb/> 98 (40.1)<lb/> 18…. Be able to concentrate better at<lb/> work (S4)<lb/> 245 2.62 (1.48) 211 (86.1)<lb/> 93 (38.0)<lb/> 152 (62.0)</table>
		</figure>


		<figure type="table">

            <head>Table </head>
 
            <label>2 </label>
 
            <head>continued<lb/> </head>
<lb/> 
            <table>Item (treatment goal)<lb/> As a result of therapy, how<lb/> important is it for you to…<lb/> n<lb/> Importance<lb/> rating<lb/> mean (SD) a<lb/> Does apply:<lb/> n (% of n = 245)<lb/> Importance rating: n (% of n = 245)<lb/> Not at all/somewhat/<lb/> moderately/<lb/> does not apply<lb/> Quite/<lb/> very<lb/> 19…. Be less burdened in your<lb/> partnership (S1)<lb/> 244 1.92 (1.57) 183 (74.6)<lb/> 143 (58.2)<lb/> 102 (41.8)<lb/> 20…. Be able to have a normal sex<lb/> life (S1)<lb/> 241 1.65 (1.62) 174 (71.0)<lb/> 161 (65.6)<lb/> 84 (34.4)<lb/> 21…. Be less dependent on doctor<lb/> and clinic visits (S2)<lb/> 244 2.47 (1.44) 213 (86.9)<lb/> 112 (45.9)<lb/> 133 (54.1)<lb/> 22…. Need less time for daily<lb/> treatment (S2)<lb/> 243 2.57 (1.40) 218 (88.9)<lb/> 104 (42.4)<lb/> 141 (57.6)<lb/> 23…. Have fewer out-of-pocket<lb/> treatment expenses (S2)<lb/> 245 2.51 (1.45) 226 (92.2)<lb/> 113 (46.1)<lb/> 132 (53.9)<lb/> 24…. Have fewer side effects (S2)<lb/> 245 2.65 (1.50) 216 (88.2)<lb/> 100 (40.8)<lb/> 145 (59.2)<lb/> 25…. Have confidence in the therapy<lb/> (S2)<lb/> 245 3.03 (1.32) 222 (90.6)<lb/> 68 (27.8)<lb/> 177 (72.2)</table>
		</figure>


		<figure type="table">

            <head>Table </head>
 
            <label>3 </label>
 
            <figDesc>Patient-rated achievement of treatment goals due to the birch pollen sublingual immunotherapy (SLIT) treatment,<lb/> as measured with the Patient Benefit Questionnaire (PBQ) within the PBI-AR (second visit; n = 216 patients who<lb/> completed the PBQ at least partially)<lb/> </figDesc>
<lb/> 
            <table>Item (treatment benefit)<lb/> The current treatment<lb/> has helped me to…<lb/> n (number of<lb/> patients who<lb/> answered this<lb/> item and did<lb/> not choose &apos;&apos;did<lb/> not apply&apos;&apos;)<lb/> Benefit<lb/> rating:<lb/> mean<lb/> (SD) a<lb/> Does apply: n (%<lb/> of n = 216)<lb/> Benefit rating: n (% of<lb/> n = 216)<lb/> Not at<lb/> all/somewhat/<lb/> moderately<lb/> Quite/<lb/> very<lb/> 1. … Not have sneezing impulses<lb/> anymore (S3)<lb/> 215<lb/> 2.26 (1.18) 216 (100.0)<lb/> 105 (48.8)<lb/> 111 (51.2)<lb/> 2. … No longer have a runny or<lb/> stuffed up nose (S3)<lb/> 214<lb/> 2.22 (1.20) 214 (99.1)<lb/> 110 (50.9)<lb/> 106 (49.1)<lb/> 3. … Be able to breathe through my<lb/> nose more freely (S3)<lb/> 211<lb/> 2.32 (1.18) 213 (98.6)<lb/> 104 (48.3)<lb/> 112 (51.7)<lb/> 4. … Feel less fatigued or groggy (S4) 205<lb/> 2.15 (1.23) 205 (94.9)<lb/> 121 (56.1)<lb/> 95 (43.9)<lb/> 5. … Be able to stay outdoors without<lb/> symptoms (S3)<lb/> 211<lb/> 2.12 (1.29) 212 (98.1)<lb/> 122 (56.4)<lb/> 94 (43.6)<lb/> 6. … Feel less irritated (S1)<lb/> 183<lb/> 1.85 (13.0) 185 (85.5)<lb/> 138 (63.9)<lb/> 78 (36.1)<lb/> 7. … Have an easily applicable<lb/> treatment (S2)<lb/> 207<lb/> 2.48 (1.27) 208 (96.3)<lb/> 96 (44.4)<lb/> 120 (55.6)<lb/> 8. … Not have itching on the eyes,<lb/> nose or palate anymore (S3)<lb/> 205<lb/> 2.24 (1.24) 205 (94.9)<lb/> 112 (51.7)<lb/> 104 (48.3)<lb/> 9. … Not have burning or watery eyes<lb/> anymore (S3)<lb/> 205<lb/> 2.25 (1.28) 206 (95.3)<lb/> 106 (49.3)<lb/> 110 (50.7)<lb/> 10. … Be healed of all symptoms (S3) 204<lb/> 1.93 (1.35) 204 (94.4)<lb/> 137 (63.2)<lb/> 79 (36.8)<lb/> 11. … Be able to sleep better (S1)<lb/> 197<lb/> 2.15 (1.28) 198 (91.6)<lb/> 123 (56.9)<lb/> 93 (43.1)<lb/> 12. … Feel less depressed (S1)<lb/> 181<lb/> 1.93 (1.26) 181 (83.8)<lb/> 132 (61.3)<lb/> 84 (38.7)<lb/> 13. … Experience a greater enjoyment<lb/> of life (S1)<lb/> 184<lb/> 1.94 (1.25) 184 (85.2)<lb/> 137 (63.6)<lb/> 79 (36.4)<lb/> 14. … Have no fear that the disease<lb/> will become worse (S1)<lb/> 184<lb/> 2.08 (1.34) 184 (85.2)<lb/> 115 (53.3)<lb/> 101 (46.7)<lb/> 15. … Be more productive in everyday<lb/> life (S4)<lb/> 207<lb/> 2.13 (1.26) 207 (95.8)<lb/> 119 (55.1)<lb/> 97 (44.9)<lb/> 16. … Be able to engage in normal<lb/> leisure activities (S4)<lb/> 209<lb/> 2.15 (1.21) 209 (96.8)<lb/> 120 (55.5)<lb/> 96 (44.5)<lb/> 17. … Be comfortable showing myself<lb/> more in public (S1)<lb/> 171<lb/> 1.85 (1.25) 174 (80.7)<lb/> 145 (67.3)<lb/> 71 (32.7)</table>
		</figure>


		<figure type="table">

            <head>Table </head>
 
            <label>3 </label>
 
            <head>continued<lb/> </head>
<lb/> 
            <table>Item (treatment benefit)<lb/> The current treatment<lb/> has helped me to…<lb/> n (number of<lb/> patients who<lb/> answered this<lb/> item and did<lb/> not choose &apos;&apos;did<lb/> not apply&apos;&apos;)<lb/> Benefit<lb/> rating:<lb/> mean<lb/> (SD) a<lb/> Does apply: n (%<lb/> of n = 216)<lb/> Benefit rating: n (% of<lb/> n = 216)<lb/> Not at<lb/> all/somewhat/<lb/> moderately<lb/> Quite/<lb/> very<lb/> 18. … Be able to concentrate better<lb/> at work (S4)<lb/> 194<lb/> 2.07 (1.22) 195 (90.2)<lb/> 125 (57.7)<lb/> 91 (42.3)<lb/> 19. … Be less burdened in your<lb/> partnership (S1)<lb/> 161<lb/> 1.75 (1.25) 163 (75.6)<lb/> 152 (70.2)<lb/> 64 (29.8)<lb/> 20. … Be able to have a normal sex<lb/> life (S1)<lb/> 153<lb/> 1.69 (1.32) 157 (72.9)<lb/> 150 (69.3)<lb/> 66 (30.7)<lb/> 21. … Be less dependent on doctor<lb/> and clinic visits (S2)<lb/> 186<lb/> 1.96 (1.30) 187 (86.5)<lb/> 130 (60.2)<lb/> 86 (39.8)<lb/> 22. … Need less time for daily<lb/> treatment (S2)<lb/> 198<lb/> 2.23 (1.29) 199 (92.1)<lb/> 110 (51.0)<lb/> 106 (49.0)<lb/> 23. … Have fewer out-of-pocket<lb/> treatment expenses (S2)<lb/> 203<lb/> 2.16 (1.35) 205 (94.9)<lb/> 120 (55.7)<lb/> 96 (44.3)<lb/> 24. … Have fewer side effects (S2) 196<lb/> 2.31 (1.29) 199 (92.0)<lb/> 109 (50.5)<lb/> 107 (49.5)<lb/> 25. … Have confidence in the<lb/> therapy (S2)<lb/> 200<lb/> 2.55 (1.32) 201 (93.0)<lb/> 85 (</table>
		</figure>


		<figure type="table">

            <head>Table </head>
 
            <label>4 </label>
 
            <figDesc>Distribution of PBI-AR scores and subdimensions on patient-relevant benefit from birch pollen sublingual<lb/> immunotherapy (SLIT) treatment<lb/> </figDesc>
<lb/> 
            <table>n<lb/> Mean (SD)<lb/> Median (IQR)<lb/> Minimum-maximum<lb/> PBI-AR global score<lb/> 212<lb/> 2.19 (1.04)<lb/> 2.38 (1.37-3.01)<lb/> 0.00-4.00<lb/> PBI-AR subscale 1: &apos; &apos;psychological burden&apos; &apos;<lb/> 192<lb/> 1.83 (1.12)<lb/> 1.88 (1.00-2.64)<lb/> 0.00-4.00<lb/> PBI-AR subscale 2: &apos; &apos;treatment burden&apos; &apos;<lb/> 202<lb/> 2.26 (0.40)<lb/> 2.41 (1.48-3.17)<lb/> 0.00-4.00<lb/> PBI-AR subscale 3: &apos; &apos;physical symptoms&apos;&apos;<lb/> 211<lb/> 2.15 (1.08)<lb/> 2.43 (1.19-3.00)<lb/> 0.00-4.00<lb/> PBI-AR subscale 4: &apos; &apos;activity/physical capability&apos; &apos;<lb/> 209<lb/> 2.06 (1.14)<lb/> 2.17 (1.05-3.00)<lb/> 0.00-4.00<lb/> PBI-AR scores range from 0 = no benefit to 4 = maximum benefit</table>
		</figure>


		<figure type="table">

            <head>Table </head>
 
            <label>5 </label>
 
            <figDesc>Comparison of PBI-AR global score indicating patient-relevant benefit from birch pollen sublingual<lb/> immunotherapy (SLIT) between patient subgroups (t-test for independent groups)<lb/> </figDesc>
<lb/> 
            <table>PBI-AR global score<lb/> n<lb/> Mean<lb/> (SD)<lb/> Difference between<lb/> means<lb/> 95% CI of difference (lower<lb/> level to upper level)<lb/> p<lb/> Male patients<lb/> 92<lb/> 2.25 (1.03)<lb/> 0.12<lb/> -0.17 to 0.40<lb/> 0.568<lb/> Female patients<lb/> 120<lb/> 2.14 (1.05)<lb/> Polyallergic patients<lb/> 127<lb/> 2.18 (1.07)<lb/> -0.01<lb/> -0.29 to 0.28<lb/> 0.954<lb/> Monoallergic patients<lb/> 85<lb/> 2.19 (1.01)<lb/> Mild rhinoconjunctivitis<lb/> 39<lb/> 2.25 (1.05)<lb/> 0.07<lb/> -0.030 to 0.45<lb/> 0.694<lb/> Severe rhinoconjunctivitis<lb/> 173<lb/> 2.17 (1.04)<lb/> Non-asthmatic patients<lb/> 160<lb/> 2.37 (0.91)<lb/> 0.75<lb/> 0.38 to 1.11<lb/> \0.001<lb/> Asthmatic patients<lb/> 52<lb/> 1.62 (1.21)<lb/> Intermittent<lb/> rhinoconjunctivitis<lb/> 65<lb/> 2.35 (0.96)<lb/> 0.25<lb/> -0.04 to 0.54<lb/> 0.094<lb/> Persistent<lb/> rhinoconjunctivitis<lb/> 146<lb/> 2.10 (1.07)<lb/> CI confidence interval<lb/> Funding. </table>
 
            <figDesc>This study was supported by a<lb/> research grant from Stallergenes GmbH,<lb/> including the Rapid Service Fee and Open<lb/> Access Fee.<lb/> Authorship. All named authors meet the<lb/> International Committee of Medical Journal<lb/> Editors (ICMJE) criteria for authorship for this<lb/> article, take responsibility for the integrity of<lb/> the work as a whole, and have given their<lb/> approval for this version to be published.<lb/> Disclosures. Christine Blome, Christopher<lb/> Neht, Julia Kisch and Nora Kressel declare that<lb/> they have no conflict of interest. Meike Hadler<lb/> is an employee of Stallergenes GmbH. Efs-<lb/>trathios Karagiannis is the Director of Global<lb/> Medical Affairs at Stallergenes Greer. Matthias<lb/> Augustin has received a research grant for this<lb/> study from Stallergenes GmbH.</figDesc>
		</figure>



    </text>
</tei>

